Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Non-Small-Cell Lung × vedolizumab × Clear all

Phase

Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Dermatologic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Myeloproliferative Disorders 1 Myelodysplastic Syndromes 1 Melanoma 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Acute 1 Graft vs Host Disease 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 323 Pemetrexed 249 Cisplatin 206 Paclitaxel 189 Docetaxel 185 Gemcitabine 143 Erlotinib Hydrochloride 130 Bevacizumab 124 pembrolizumab 115 Radiotherapy 100 Nivolumab 78 durvalumab 76 osimertinib 70 Drug Therapy 70 atezolizumab 51 Vinorelbine 49 Gefitinib 48 Radiosurgery 42 130-nm albumin-bound paclitaxel 34 Taxes 32 Cetuximab 32 Magnetic Resonance Spectroscopy 31 Surgical Procedures, Operative 30 Ipilimumab 30 Albumin-Bound Paclitaxel 28 Etoposide 26 tislelizumab 25 icotinib 25 anlotinib 25 Specimen Handling 25

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06646016 2025-12-26

EPIC

Therakos LLC

Phase 2 Withdrawn

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡